THERAPY DOSSIER · th-8621ee949e49

Sesamin

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL479911 ↗
ChEMBL max phase: Not recorded
Synonyms: (+)-Sesamin
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT05678439 ↗NAcompleted

Sesamin on Sleep Quality and Antioxidative Status in Low Arousal Threshold OSA

Sleeping Disorders

Enrolment: 33 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31964241 ↗2020Reported benefit

Sesamin promotes angiogenesis and accelerates wound healing in rats via alleviates TBHP-induced apoptosis in human umbilical vein endothelial cells.

RatWoundSprague-Dawley

Model: Cutaneous wound in rats, with parallel tert-butyl hydroperoxide-induced apoptosis in human umbilical vein endothelial cells

Sesamin dose-dependently increased endothelial proliferation, adherence, migration and angiogenic capacity, attenuated tert-butyl hydroperoxide-induced apoptosis, and accelerated granulation tissue formation and collagen deposition and remodelling in rat wounds.

Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.

Loading the evidence…